These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37325052)

  • 1. Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer.
    Ma W; Tian M; Hu L; Ruan X; Zhang W; Zheng X; Gao M
    J Cancer; 2023; 14(9):1592-1604. PubMed ID: 37325052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma.
    Tang T; Zhou J; Zhang LX; Yang G; Li WN; Zhu JJ; Xiong YF; Li JD
    Anticancer Agents Med Chem; 2023 Feb; ():. PubMed ID: 36786145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
    Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
    Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin C sensitizes BRAF
    Su X; Li P; Han B; Jia H; Liang Q; Wang H; Gu M; Cai J; Li S; Zhou Y; Yi X; Wei W
    J Exp Clin Cancer Res; 2021 Jan; 40(1):34. PubMed ID: 33468157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
    Lu H; Liu C; Huynh H; Le TBU; LaMarche MJ; Mohseni M; Engelman JA; Hammerman PS; Caponigro G; Hao HX
    Oncotarget; 2020 Jan; 11(3):265-281. PubMed ID: 32076487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram/Cu Kills and Sensitizes
    Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
    [No Abstract]   [Full Text] [Related]  

  • 9. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.
    Li Y; Yuan Y; Zhang F; Guo A; Cao F; Song M; Fu Y; Xu X; Shen H; Zheng S; Pan Y; Chang W
    Front Pharmacol; 2021; 12():739501. PubMed ID: 34790119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
    Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
    Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
    Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
    Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
    Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
    Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
    Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
    Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.
    Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG
    Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 20. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.